Opiate Dependence: Clinical Trials

19 trials for Opiate Dependence, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 completed. 19 Phase 2, 3 Phase 3, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 219Completed 19
Phase 33Completed 3
Phase 12Completed 2

Follow Opiate Dependence: new trials by email Literature Review of Opiate Dependence trials Research Report on Opiate Dependence

Trials (filtered) newest first · largest first

All 19 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Impact of Lofexidine on Stress, Craving and Opioid Use
Lofexidine, Placebo - Opioid-use Disorder, Opiate Dependence
Phase 2CompletedMedical University of South Carolina1122019-06-262025-02-07
Remote Observed Dosing of Suboxone to Improve Clinical Practice
Suboxone Remote Observed Dosing, Suboxone Attention Control - Opioid-use Disorder, Opioid Dependence
Phase 1 / Phase 2CompletedUniversity of Pennsylvania162019-04-012023-07-27
Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone
extended release naltrexone - Opiate Dependence
Phase 2 / Phase 3CompletedUniversity of Pennsylvania1462016-01-012021-01-28
Clinical Efficacy and Serum Proteomic Profiling of Suan-Zao-Ren Tang for Sleep Disturbance During Methadone Maintenance
Suan-Zao-Ren Tang, Suan-Zao-Ren Tang placebo - Opiate Dependence
Phase 2CompletedChina Medical University, Taiwan902013-07-012014-03-18
Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone
injectable naltrexone, placebo comparator - Opiate Dependence, Human Immunodeficiency Virus
Phase 2 / Phase 3CompletedUniversity of Pennsylvania772013-06-012020-11-06
Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia
Atomoxetine - Opiate Dependence, Stimulant Dependence
Phase 2CompletedYale University902013-05-012017-04-27
Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence
very low dose naltrexone, extended release naltrexone, buprenorphine/naloxone - Opiate Dependence
Phase 2CompletedPaolo Mannelli382012-09-012016-06-01
Clinical Trial of Integrated Treatment for Pain and Opioid Dependence
CBT, Buprenorphine, Educational Counseling - Opiate Dependence, Chronic Pain
Phase 1 / Phase 2CompletedYale University902009-09-012021-08-02
Employment-Based Depot Naltrexone Clinical Trial II
Work Plus Naltrexone Contingency - Opiate Dependence
Phase 2CompletedJohns Hopkins University382008-05-012018-01-23
Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid Dependence
Enhanced Sexual Risk Management, Standard Sexual Risk Management - Opiate Dependence, HIV Infections
Phase 2CompletedYale University222006-07-012020-04-03
Employment-Based Depot Naltrexone Clinical Trial
employment-based reinforcement - Opiate Dependence
Phase 2CompletedJohns Hopkins University352006-05-012017-12-26
Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction
Go Medical Naltrexone implants - Opiate Dependence
Phase 2 / Phase 3CompletedUniversity of Oslo562006-01-012009-05-05
CRAFT Behavior Therapy: Treatment Entry Component
Community Reinforcement and Family Training, Treatment Entry Training, 12- step Al/Nar- Anon Facilitation - Drug Addiction, Stimulant Dependence
Phase 2CompletedTreatment Research Institute1802006-01-012023-03-28
Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants
Clinic-based substance abuse treatment with buprenorphine, Case management and referred substance abuse treatment - Opiate Dependence, HIV Seropositivity
Phase 2CompletedJohns Hopkins University1202005-11-012015-04-15
Effectiveness of Tiagabine for Cocaine Dependence in Methadone-Maintained Individuals - 1
Tiagabine - Cocaine-Related Disorders, Opiate Dependence
Phase 2CompletedNational Institute on Drug Abuse (NIDA)802004-12-012017-01-12
Brief Introductory Therapy for Opioid Dependence
Standard drug counseling, BDRC - Opiate Dependence, HIV Infections
Phase 2CompletedYale University512004-09-012020-04-02
HIV Risk Reduction and Drug Abuse Treatment in Malaysia
Buprenorphine/Subutex, Naltrexone, Drug counseling - Opiate Dependence
Phase 2CompletedYale University1802003-04-012020-03-31
Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence
depot naltrexone, Compliance enhancement (CE), BNT - Opiate Dependence
Phase 2CompletedNew York State Psychiatric Institute1252002-06-012012-10-26
ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids
Medisorb naltrexone 75 mg, Medisorb naltrexone 150 mg, Medisorb naltrexone 300 mg - Opiate Dependence
Phase 2CompletedAlkermes, Inc.272002-03-012017-01-11

Narrower conditions

Opioid-Related Disorders (19)  ·  Substance-Related Disorders (4)  ·  HIV Infections (3)  ·  Acquired Immunodeficiency Syndrome (2)  ·  Cocaine-Related Disorders (2)  ·  Alcoholism (1)  ·  Behavior, Addictive (1)  ·  Chronic Pain (1)  ·  HIV Seropositivity (1)  ·  Heroin Dependence (1)  ·  Risk Reduction Behavior (1)

Broader conditions

Chemically-Induced Disorders (19)  ·  Mental Disorders (19)  ·  Narcotic-Related Disorders (19)  ·  Substance-Related Disorders (15)  ·  Blood-Borne Infections (4)  ·  Communicable Diseases (4)  ·  Genital Diseases (4)  ·  Immune System Diseases (4)  ·  Immunologic Deficiency Syndromes (4)  ·  Infections (4)  ·  Lentivirus Infections (4)  ·  RNA Virus Infections (4)  ·  Retroviridae Infections (4)  ·  Sexually Transmitted Diseases (4)  ·  Sexually Transmitted Diseases, Viral (4)

Interventions

Buprenorphine (3)  ·  Naltrexone (3)  ·  vivitrol (3)  ·  Analgesics, Opioid (1)  ·  Atomoxetine Hydrochloride (1)  ·  Buprenorphine, Naloxone Drug Combination (1)  ·  Case Management (1)  ·  Hydromorphone (1)  ·  Naloxone (1)  ·  Practice Management (1)  ·  Tiagabine (1)  ·  lofexidine (1)

Sponsors

Yale University (5)  ·  Johns Hopkins University (3)  ·  University of Pennsylvania (3)  ·  Alkermes, Inc. (1)  ·  China Medical University, Taiwan (1)  ·  Medical University of South Carolina (1)  ·  National Institute on Drug Abuse (NIDA) (1)  ·  New York State Psychiatric Institute (1)  ·  Paolo Mannelli (1)  ·  Treatment Research Institute (1)  ·  University of Oslo (1)

Countries

United States (13)  ·  Malaysia (2)  ·  Norway (1)  ·  Russia (1)  ·  Taiwan (1)

Top investigators

George E Woody, MD (2)  ·  Kenneth Silverman, Ph.D. (2)  ·  Bernard L. Silverman, MD (1)  ·  Brenda Curtis, PhD (1)  ·  Edward Nunes, MD (1)  ·  Gerardo Gonzalez, M.D. (1)  ·  Gregory M Lucas, MD, PhD (1)  ·  Helge Waal, MD (1)  ·  Helge Waal, Professor (1)  ·  Kimberly C Kirby, Ph.D. (1)  ·  Kyle Kampman, MD (1)  ·  Lynn E Sullivan, MD (1)  ·  Mahmud Mazlan, M.D. (1)  ·  Marek C Chawarski, Ph.D. (1)  ·  Paolo Mannelli, MD (1)

Results publications

PMID 21782353, PMID 18586174, PMID 20513828, PMID 20707781, PMID 21320227, PMID 22079773, PMID 27574837, PMID 34737091, PMID 37231479, PMID 40342086

NIH funding

R01DA019497 (2), R01DA010746 (1), R01DA013108 (1), R01DA014718 (1), R01DA018696 (1), R01DA024695 (1), R01DA033670 (1), U34DA045177 (1), U54DA016511 (1)